Nutex Health Addresses Recent Short Seller Report and Clarifies Facts

Nutex Health Responds to Allegations from Short Seller

Nutex Health Inc. (NASDAQ: NUTX), a distinguished healthcare management firm operating out of Houston, Texas, has recently found itself in the spotlight due to allegations stemming from a short seller report published by Capybara Research on November 25, 2025. The company's management is well aware of these claims and has issued a detailed response to clarify its position.

The report by Capybara Research has raised eyebrows for its dubious credibility. Nutex Health pointed out that there is little to no verifiable information about Capybara as an entity, suggesting that it could be a phantom group lacking legitimacy. Capybara has faced legal actions in the past, with other entities attempting to bring lawsuits against them that could not be executed due to the alleged concealment of their identity and location by those behind Capybara Research.

Nutex Health perceives the publication as an intentional effort to create market uncertainty designed to profit from the resultant drop in stock value. This tactic, unfortunately, is not new and has become prevalent among short sellers who seek to undermine the standing of public companies through misleading narratives.

In their response, Nutex Health emphasized that the allegations made in the report are groundless and built on obsolete, irrelevant, or incorrect information. Furthermore, the company has detailed its material legal proceedings in its most recent 10-Q report, providing transparency regarding its legal affairs to all stakeholders. These disclosures cover any disputes involving the company, alongside a thorough analysis of related party transactions found in the company's financial statements.

The facts presented in Nutex’s filings provide a robust picture of operational integrity, countering the insinuations made in Capybara’s report. The company's management team, underlining their commitment to accuracy, has decided against further commentary about the short seller's assertions. Instead, they choose to continue focusing on their healthcare operations, ensuring that stakeholder interests are safeguarded through a commitment to transparency and truthfulness.

Founded in 2011, Nutex Health operates through two main divisions: a Hospital Division and a Population Health Management Division. The Hospital Division is responsible for managing micro-hospitals and other healthcare facilities across 11 states, while the Population Health Management Division works with provider networks to ensure effective health services and operational excellence. This multifaceted approach has established Nutex as a leader in innovative healthcare solutions.

Alongside this firm response to misinformation, Nutex Health remains committed to its strategic growth plans and operational principles. Looking ahead, they aim to execute their objectives while maintaining rigorous scrutiny over their operational standards. Invested parties have been reminded of the importance of reviewing the company's official filings to ascertain the true state of its affairs.

In conclusion, Nutex Health invites stakeholders to disregard the misleading claims made by Capybara Research and instead to focus on the proven track record of the company and its steadfast commitment to providing exemplary healthcare services. This situation serves as a timely reminder of the challenges public enterprises face in today's market environment, especially against the backdrop of malevolent practices employed by some market adversaries. The company continues to uphold its values while navigating through these turbulent corridors of market speculation.